Slide 1: The Transplant Company Earnings Presentation Q3 2022
Leslie M, Kidney Transplant Recipient Focused on improving care across the entire transplant patient journey The Transplant Company™ Earnings Presentation Q3 2022
Slide 2: Forward-looking statements
These slides and the accompanying oral presentation contain forward-looking statements, including statements with respect to expectations regarding CareDx’s upcoming milestones, vision and 2022 revenue guidance. All statements other than statements of historical fact contained in this presentation,
Slide 3: Our Mission and Vision
Our Mission We are committed to improving long-term outcomes by providing innovative solutions throughout the entire transplant patient journey Our Vision The leading partner for the transplant ecosystem
Slide 4: Q3 Earnings: Key Topics for Discussion
Q3 Earnings: Key Topics for Discussion 4 • Differentiated financial profile • Driving future growth through the 3 C’s – Catalysts, Collections, Coverage • Building leadership in the transplant ecosystem
Slide 5: Q3 Financial and Operational Highlights
Q3 Financial and Operational Highlights 5 $291M Cash & equivalents No near-term cash needs Balance Sheet1 64% GAAP 67% Adjusted 74% Testing services2 Gross Margin2 46,500 Tests Up 3% sequentially and 15% y/y Volume Growth $79.4M Up 5% y/y Revenue Net loss ($16.9M) Adjusted EBITDA ($2.5M) Profitabili
Slide 6: Kidney, Heart and Lung Transplant Volume Trends
Kidney, Heart and Lung Transplant Volume Trends 6 Source: UNOS Monthly Kidney/Heart/Lung Single Organ Transplants 6977 7976 7357 7119 7118 7568 7870 4000 5000 6000 7000 8000 9000 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 Quarterly Transplant Volumes -1% 14% -8% -3% 0% 6% 4% -10% -5% 0% 5% 10% 15% 20% 1Q21
Slide 7: Extending Leadership in Transplant
Extending Leadership in Transplant Strong Progress Across All Organs 7 >90% Center penetration >95% HeartCare attach rate Heart Testing Services Launched 2005 >75% Center penetration >100 Protocols Kidney Testing Services Launched 2017 60% Center penetration >2,000 Tests Lung Testing Services Launch
Slide 8: Upcoming Growth Drivers – Catalysts, Collections, Coverage
Upcoming Growth Drivers – Catalysts, Collections, Coverage 8 •AlloMap Kidney Launch •UroMap Submission to CMS and eventual launch Pipeline Catalysts • Increase Medicare Advantage collection efficiency •Scaled up infrastructure Improving Collections •cfDNA in ISHLT Guidelines •AlloSure Lung CMS •Allo
Slide 9: ASP on Reimbursed Tests
9 ASP on Reimbursed Tests $- $1,000 $2,000 $3,000 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 All Paid Test ASP Trend (Testing Qtr) FLAT Source: data on file as of 9/30/22
Slide 10: Our Vision: The Leader in The Transplant Ecosystem
Post Transplant Biomarkers Our Vision: The Leader in The Transplant Ecosystem 11 Leadership across the patient journey Electronic Medical Records Quality & Analytics Transplant focused App Medication Discharge CareDx is #1 CareDx is #1 CareDx is #1 CareDx is #2 CareDx is #2 Over 100,000 transplant p
Slide 11: Your Partner in Transplant Care
é Care Dx’ Your Partner in Transplant Care 6 é CareDx’
Slide 12: Appendix
Appendix 16 é CareDx:
Slide 13: Reconciliation of Non-GAAP Gross Margin
Reconciliation of Non-GAAP Gross Margin FY 2018 FY 2019 FY 2020 FY 2021 Q1 2022 Q2 2022 Q3 2022 Revenue 76.6 127.1 192.2 296.4 79.4 80.6 79.4 GAAP Cost of Revenue 33.0 45.5 63.1 97.4 26.9 27.5 28.3 Stock-based compensation expense (0.8) (2.2) (2.3) (3.7) (0.4) (1.4) (1.1) Acquisition related amortiz
Slide 14: Reconciliation of Adjusted EBITDA
Reconciliation of Adjusted EBITDA FY 2018 FY 2019 FY 2020 FY 2021 Q1 2022 Q2 2022 Q3 2022 GAAP Net Loss (46.8) (22.0) (18.7) (30.7) (19.6) (21.7) (16.9) Stock-based compensation expense 7.1 22.4 23.4 36.1 10.6 12.6 11.2 Impairments & Write-downs - 0.2 - 2.4 - - 0.8 Unrealized gain on investments - -